Otsuka Bolsters Pipeline with Acquisition of Antibody Developer Visterra
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 7 (Table of Contents)
Published: 28 Jul-2018
DOI: 10.3833/pdr.v2018.i7.2340 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Looking to focus its efforts in proprietary drug discovery and development platforms, Otsuka Pharmaceutical has acquired the biotech firm, Visterra, to venture into the antibody space for an all-cash transaction of US$430 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS